Sanofi American Depositary Receipt (SNY)
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States
The FDA approves Sanofi's Qfitlia as the first therapy in the United States to treat hemophilia A or B with or without inhibitors.
US FDA approves Sanofi's bleeding disorder therapy
The U.S. Food and Drug Administration approved French drugmaker Sanofi's therapy, paving the way for a new type of treatment for patients 12 years of age and older with a rare disorder that prevents blood from clotting properly, the regulator said on Friday.
Sanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track Tag
The FDA bestows a fast-track designation to SNY's mRNA vaccine candidate for the prevention of chlamydia infection.
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)
If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in multiple sclerosis.
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib
If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in multiple sclerosis.
Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug
Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company.
Sanofi to acquire Dren Bio's immunology unit
Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201.
Sanofi Stock Forms Golden Cross As Dupixent Eyes FDA Green Light: Can The Bullish Run Continue?
Sanofi NV SNY has been flexing its biotech muscles, and investors are taking notice. The stock is firmly in bullish territory, recently forming a Golden Cross , a classic technical signal that often precedes further gains.
Top 3 Health Care Stocks That May Keep You Up At Night In Q1
As of March 11, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
South African watchdog probes Novo Nordisk and Sanofi over insulin
South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive practices in the human insulin pen market, the authority said on Tuesday.
Health Rounds: Experimental Sanofi drug delays heart valve disease progression, and potentially surgery
An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart problem, in clinical trials, potentially preventing the need for surgery, researchers reported.
Sanofi: OpenAI's Research Agents Could Lead To Explosive Growth
Sanofi's deep partnership with OpenAI could be a huge differentiating factor as OpenAI's agentic models grow in capabilities. OpenAI's "Deep Research" tool is already incredibly promising for Sanofi in its ability to dramatically boost the productivity of researchers. Sanofi's strong financials provide a solid base to fuel AI-driven growth.
